A current ongoing phase 3 clinical trial EXCLAIM-2 (NCT04129502) was initiated to assess the safety and efficacy of first-line mobocertinib versus platinum-based chemotherapy in patients with ex20ins EGFR locally advanced or metastatic NSCLC [184]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.